Chelsea Labs requests hearing on proposal to withdraw ANDAs
Executive Summary
Counsel for Chelsea (D.C. law firm King & Spalding), requests hearing on FDA's proposal to withdraw approval of nine of Chelsea's ANDAs ("The Pink Sheet" June 25, "In Brief").